It’s time to rejoice those who have been suffering from chronic migraine and related issues. Aimovig, a drug that promises preventive treatment of migraine in adults, has been now approved by The US Food and Drug Administration. The medicine would work by preventing the function of calcitonin gene-related peptide — which has an important role in causing migraine in adults. The drug is expected to be a savior for thousands of affected people worldwide. The drug, which should be taken in form of injections every month, will now be available for purchase across the United States. This drug is the first in its class to get FDA approval.
Preventive treatment of Migraine has been an important thing for a very long time. As of now, patients are prescribed with other pills and medicines, which do not have an actual impact on the frequency of chronic migraine. For the same reason, most of these drugs are not used by patients. With the availability of Aimovig, however, the situation should change drastically. The FDA adds in its press release that “the effectiveness of Aimovig for the preventive treatment of migraine was evaluated in three clinical trials. The first study included 955 participants with a history of episodic migraine and compared Aimovig to placebo. Over the course of six months, Aimovig-treated patients experienced, on average, one to two fewer monthly migraine days than those on placebo.
Aimovig, however, is priced a bit higher. For a year, the drug would cost $6900, without insurance. While its effectiveness in preventing and removing chronic migraine has been found out by the research team, there is no valid information on the long-term safety offered by the drug. Customers will have to wait until suitable information has been provided in the long run. However, Aimovig has been considered a huge success for those who have been struggling with the symptoms and difficulties of chronic migraine.